Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apololitowereili monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Fujian Provincial Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Apololitowereili monoclonal antibody is an investigational therapeutic agent currently being evaluated in clinical trials for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinomas. Developed by the Fuzhou University Affiliated Provincial Hospital, it is being studied in a Phase 2 neoadjuvant setting in combination with the FLOT chemotherapy regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel). The primary focus of current research is its efficacy and safety in patients with resectable, locally advanced, HER2-negative, microsatellite stable (MSS) or microsatellite instability-low (MSI-L), and PD-L1-positive gastric or GEJ adenocarcinoma. While the specific biological target of apololitowereili is not explicitly detailed in the provided registry information, its use in PD-L1-positive populations suggests a role in immune checkpoint modulation or targeted immunotherapy.
- Other names
- apololitowereili monoclonal antibody
Beyond the preview
Go deeper on apololitowereili monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apololitowereili monoclonal antibody.